Literature DB >> 22404411

Letter: the ethics of using inferior regimens in H. pylori randomised trials.

D Y Graham, L A Fischbach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22404411     DOI： 10.1111/j.1365-2036.2011.04944.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  3 in total

1.  Is concomitant quadruple therapy for Helicobacter pylori eradication really needed for Japanese patients?

Authors:  Vincenzo De Francesco; Angelo Zullo; Cesare Hassan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-12-06

2.  Empiric H. pylori therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best.

Authors:  Yoshio Yamaoka; David Y Graham
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

3.  Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial.

Authors:  Joon Sung Kim; Byung-Wook Kim; Su Jin Hong; Jin Il Kim; Ki-Nam Shim; Jie-Hyun Kim; Gwang Ho Baik; Sang Wook Kim; Hyun Joo Song; Ji Hyun Kim
Journal:  Gut Liver       Date:  2016-07-15       Impact factor: 4.519
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.